BamSEC and AlphaSense Join Forces
Learn More

Candel Therapeutics Inc. – Material Contracts

NASDAQ: CADL    
Share price (7/7/26): $9.85    
Market cap (7/7/26): $722 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 13 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages First Amendment to Master Production Services Agreement
12/34/56
EX-10.21
from 10-K 62 pages Certain Confidential Information, Marked by [***] Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Purchase and Sale Agreement by and Between Candel Therapeutics, Inc. and 4010 Royalty Investments Icav, an Umbrella Irish Collective Asset-Management Vehicle With Segregated Liability Between Sub-Funds, for and on Behalf of Its Sub-Fund, 4010 Royalty Investments Fund 1 Dated as of February 19, 2026
12/34/56
EX-10.20
from 10-K 4 pages Candel Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.19
from 10-K 24 pages Candel Therapeutics, Inc. 2025 Inducement Plan
12/34/56
EX-10.2
from 8-K 5 pages Omnibus Amendment, Release and Waiver to Warrants to Purchase Common Stock
12/34/56
EX-10.1
from 8-K 75 pages Article 1 Definitions
12/34/56
EX-10.1
from 8-K 6 pages Statement of Amendment
12/34/56
EX-10.1
from 8-K 24 pages Candel Therapeutics, Inc. Securities Purchase Agreement Agreement
12/34/56
EX-10.19
from 10-K 9 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 9 pages Amendment to Exclusive License Agreement
12/34/56
EX-10
from 10-K 43 pages Master Production Services Agreement
12/34/56
EX-10.1
from 10-Q 13 pages Employment Agreeement
12/34/56
EX-10.1
from 10-Q 13 pages Employment Agreeement
12/34/56
EX-10.8
from 10-Q 13 pages Employment Agreeement
12/34/56
EX-10.13
from 10-K 10 pages Revised Consulting Agreement – Effective October 1, 2021
12/34/56
EX-10.12
from 10-K 24 pages Employment Agreeement
12/34/56
EX-10.10
from S-1/A 56 pages Lease of Premises at 117 Kendrick Street, Needham, Massachusetts From 117 Kendrick De, LLC to Advantagene, Inc. D/B/a Candel Therapeutics
12/34/56
EX-10.9
from S-1/A 39 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. the Brigham and Women’s Hospital, Inc. Exclusive Patent License Agreement Bwh Agreement No: [***] Bwh Case No: [***], [***], and [***]
12/34/56
EX-10.7
from S-1/A 23 pages Article 1 Definitions
12/34/56